Reply from the Authors: We thank Dr. Canetti-Nakson for his comments, and we would like to answer as follows. We believe it is important to consider the original paper when a new idea is proposed. One concept of "ataxic hemiparesis"1 allows uncertainty because when one sees a patient with pure hemiparesis after a stroke, the misdiagnosis of "ataxic hemiparesis" may be made because of hemiparesis and clumsiness of limb which may resemble ataxia. "Ataxic hemiparesis" must be limited to cases of lacunar stroke because of the diagnostic and therapeutic implications; patients with "ataxic hemiparesis" have a n excellent prognosis. Anticoagulant therapy and angiography are not indicated, as shown by Fisher's cases.
Therefore, it does not seem appropriate to use the term "ataxic hemiparesis" in cases of brain tumor in demyelinating diseases that show the combination of ipsilateral pyramidal signs and cerebellar-like ataxia; "ipsilateral pyramidal and cerebellar signs" would be preferable.
Answer to comment 1. Perman and Racy reported "homolateral ataxia and crural paresis" and CT demonstrated the responsible lesion in the superior portion of the posterior limb of the internal capsule and thalamus, but not in the upper pons.' Fisher reported that infarcts a t sites other than the upper pons do not cause the same combination of signs.' In addition, sensory loss in the case of Perman and Racy differed from Fisher's original report.
Bendheim and Berg reported "ataxic hemiparesis from a midbrain mass."3 However, their case was not cerebrovascular disease, but a mass lesion associated with leukemia.
Fisher syndrome in childhood
T o the Editor: The paper of Becker e t all on Fisher syndrome in children was informative but it invites comments. First, they seem to be unaware of our CT demonstration of a midbrain lesion in a child with ataxia, ophthalmoplegia, and hyporeflexia.' Indeed the possibility of a central mechanism underlying the syndrome had already been raised by others.:I. 4 Second, despite their reference to the possibility of central mechanisms the authors seem unable to divorce themselves from traditional views of the pathogenesis of the Guillain-Barre syndrome in general or the Fisher syndrome in particular. I believe this is a mistake if there is a possibility of anterograde disorder in a peripheral nerve after injury of its centrally-located perikaryon. The following clinical observations therefore argue for central lesions in infectious polyneuritis: entirely or predominantly motor disorders; predominantly distal or proximal motor manifestations in different patients; paucity (or absence) of autonomic symptoms and the usual preservation of sphincter functions; more rapid recovery in most patients than expected for axonal regeneration; demonstration of central lesion in Fisher syndrome;*.5 genuine Babinski response in otherwise "typical" Guillain-Barre syndrome (personal observations); and optic neuritis (i.e., involvement of the central nervous system) in infectious polyneuritis. 6 Regarding the pupil in Fisher syndrome,',' as Becker et a1 observed, both components of the Holmes-Adie syndrome are seen in some patients with Fisher syndrome.2.4 Whereas the currently accepted "ganglionic" notion of the Holmes-Adie pupils is clearly irrelevant in relation to the coexisting hyporeflexia, a strategically located midbrain lesion (figure) could explain that association (i.e., interrupting the descending facilitator fibers to the spinal cord*). On the other hand a midbrain lesion could (by transynaptic neuronal degeneration) affect the ciliary ganglion,7.8 but leave the hyporeflexia unexplained.
I . Derakhshan Reply from the Authors: The child reported by Price et a1 with Fisher syndrome had evidence of concomitant infection with infectious mononucleosis, one of the infections that may be associated with this syndrome. We regret having omitted this reference. We thank Dr. Tomsak for bringing it to our attention. We thank Drs. Derakhshan, Lotfi, and Kaufman for drawing our attention to their interesting paper. The patient had features similar to patients accepted as having Fisher syndrome. The fact that the child had a lower facial weakness, hypoactive rather than absent stretch reflexes, and a Babinski sign, however, would not be accepted as typical of this entity. On the basis of the extraordinary CT scan findings the disorder she had was not Fisher syndrome as these authors agree. It seems reasonable to propose that the demonstrated CT midbrain lesion provides some support for the contention that a midbrain (central) lesion may be involved in patients with Fisher syndrome. On the other hand, a wealth of evidence suggests a peripheral rather than a central site for the pathological lesion in the GuillainBarre syndrome.'
Phenobarbital dosing in neonates and asphyxia
To the Editor: While Fischer et all emphasize the wide interpatient variability in the disposition of phenobarbital in neonates, factors such as prenatal phenobarbital exposure, postnatal age, duration of phenobarbital therapy, and concurrent disease states were not evaluated for possible influence on phenobarbital clearance. Data from previous studies show that these factors confound the rate of phenobarbital elimination.' 1 We evaluated the possible association of neonatal asphyxia with phenobarbital disposition in 18 neonates with seizure disorders and our data suggest that asphyxia may account for substantial reduction in phenobarbital clearance. Phenobarbital 15 mg per kilogram loading doses were given intravenously. Serum phenobarbital concentrations were determined two hours later by EMIT immunoassay. Daily maintenance doses of 2.5 to 5 mg per kilogram were selected and steady-state serum concentrations were checked a t least weekly. The criteria for neonatal asphyxia included either: (1) an Apgar score at 1 or 15 minutes of 3 or less, (2) cardiac or respiratory arrest requiring resuscitation, (3) a Po, below 30 mm Hg documented on two consecutive blood gases while the neonate was receiving 100% oxygen, or (4) apnea lasting at least one minute and requiring bagging.
Pharmacokinetic calculations were performed to determine the apparent volume of distribution (V) and the apparent total body clearance ((21,) using the for- The reason for the reduced clearance in neonates who have been asphyxiated is unknown. Both liver and kidney are probably damaged by asphyxia so that drug elimination is reduced. Dosing guidelines should reflect the presence or absence of asphyxia. If the goal is to achieve a serum phenobarbital concentration of 20 mg per liter, asphyxiated neonates should receive 1.8 mg per kilogram per day and the dose for nonasphyxiated neonates should be 4.0 mg per kilogram per day. us to review our raw data. Of our 15 patients, ten suffered from severe asphyxia due to respiratory distress syndrome, meconium aspiration, prolapsed cord, or other causes. As shown in the table, their disappearance rates, half-lives, and total body clearances of phenobarbital did not differ from the five infants who were not asphyxiated. Contrary to Gal et al, Painter e t a13 demonstrated only that duration of therapy influences disposition of phenobarbital in newborns; Jalling et a12 studied disappearance of phenobarbital in infants who received phenobarbital transplacentally when their mothers were treated for complications of pregnancy.
The method of pharmacokinetic calculation used by Gal et a1 differs in important ways from ours. We determine volume of distribution by calculating the theoretical concentration at time zero from the disappearance rate after a single dose. Although their volume of distribution value does not differ from ours, it is calculated from a blood concentration arbitrarily obtained two hours after the loading dose. While calculation of clearance by their formula may allow estimation of an appropriate daily dose, it does not necessarily reflect clearance because no consideration is given to differences in gastrointestinal absorption, compartmentalization, or storage within the body.
Both their data and ours indicate that frequent determination of plasma blood levels is essential to maintain therapeutic blood concentrations of phenobarbital in these patients. Steady state is probably never achieved because of rapid growth and continued maturation of enzymatic systems in the newborn infant. These factors make it even less appropriate to calculate clearance on the basis of daily dose requirements.
